Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Starting empagliflozin in people on insulin and with good glycaemic control
+Practice
In print
PHARMACOTHERAPY
Starting empagliflozin in people on insulin and with good glycaemic control
Wednesday 3 March 2021, 12:35 AM

Increased blood glucose monitoring is encouraged when starting empagliflozin
Your patient uses gliclazide and insulin but could still benefit from the additional cardiovascular and renal protections of empagliflozin. How would you manage the change in treatment?
Key points, Empagliflozin reduces the renal and cardiovascular complications of type 2 diabetes, even when blood glucose level is well controlled.
Empagliflozi, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
- Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2012;372:m4573.
- Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117–28.